Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema.
OBJECTIVE
To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME).


METHODS
Interventional case series.


METHODS
Two patients with ICME were treated with intravitreal triamcinolone.


RESULTS
In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 microm before and 197 microm posttreatment in the right eye and 542 microm before and 190 microm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 microm before and 208 microm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients.


CONCLUSIONS
Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.
D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007368:Interferometry; D008027:Light; D008269:Macular Edema / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012008:Recurrence; D014054:Tomography; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide